Published in Cornea on April 01, 1990
Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol (2009) 2.19
Characterization of effector T cells in dry eye disease. Invest Ophthalmol Vis Sci (2009) 1.21
Expression of human beta-defensins in conjunctival epithelium: relevance to dry eye disease. Invest Ophthalmol Vis Sci (2003) 1.09
Dry eye disease and microbial keratitis: is there a connection? Ocul Surf (2013) 0.92
Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye-associated corneal inflammation. Invest Ophthalmol Vis Sci (2009) 0.88
Sterile corneal perforations in a case of severe dry eyes. Med J Armed Forces India (2013) 0.83
Cornea: Window to Ocular Immunology. Curr Immunol Rev (2011) 0.81
Spontaneous episodic decreased tear secretion in rats is related to opioidergic signaling pathways. Invest Ophthalmol Vis Sci (2012) 0.76
A Case of Bilateral Corneal Perforation in a Patient with Severe Dry Eye. J Clin Diagn Res (2017) 0.75
Scleritis-associated uveitis. Ophthalmology (1997) 7.34
Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology (1992) 6.62
The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med (1999) 5.79
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol (2000) 4.70
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol (1996) 3.04
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) 2.68
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
Severity of scleritis and episcleritis. Ophthalmology (1994) 2.43
Anterior chamber crystals following hyphema. Arch Ophthalmol (1990) 2.39
Elevated vitreous interleukin-10 level is not diagnostic of intraocular-central nervous system lymphoma. Ophthalmology (1999) 2.33
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
Infectious endophthalmitis. Review of 36 cases. Ophthalmology (1982) 2.26
Human adenoviruses and coliphages in urban runoff-impacted coastal waters of Southern California. Appl Environ Microbiol (2001) 2.18
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer (2012) 2.15
Cicatricial pemphigoid. Trans Am Ophthalmol Soc (1986) 2.10
Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res (2000) 1.99
Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology (1995) 1.98
Histopathologic types of benign breast lesions and the risk of breast cancer: case-control study. Am J Surg Pathol (2002) 1.91
Mitomycin eye drops as treatment for pterygium. Ophthalmology (1988) 1.89
Immunomodulatory therapy for chronic tubulointerstitial nephritis-associated uveitis. Am J Ophthalmol (2000) 1.84
The characteristic features of optical coherence tomography in posterior uveitis. Br J Ophthalmol (2007) 1.78
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer (2009) 1.77
Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol (1997) 1.71
Monoclonal antibodies to the human mammary gland. I. Distribution of determinants in non-neoplastic mammary and extra mammary tissues. Virchows Arch A Pathol Anat Histol (1982) 1.68
Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea (1991) 1.65
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer (2008) 1.62
Schirmer test after topical anesthesia and the tear meniscus height in normal eyes. Arch Ophthalmol (1979) 1.62
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60
Posterior capsule opacification after cataract surgery in patients with uveitis. Ophthalmology (1997) 1.59
Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology (1999) 1.57
An analysis of therapeutic decision for scleritis. Ophthalmology (1993) 1.55
Wegener's granulomatosis: the relationship between ocular and systemic disease. J Rheumatol (2001) 1.55
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology (2001) 1.54
The value of combined serum angiotensin-converting enzyme and gallium scan in diagnosing ocular sarcoidosis. Ophthalmology (1995) 1.54
Ocular features associated with anticardiolipin antibodies: a descriptive study. Am J Ophthalmol (2001) 1.53
Ocular syphilis. Ophthalmology (1990) 1.53
Ocular Whipple's disease: earlier definitive diagnosis. Ophthalmology (2001) 1.50
Increasing the diagnostic yield of conjunctival biopsy in patients with suspected ocular cicatricial pemphigoid. Ophthalmology (1995) 1.48
Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology (1984) 1.46
An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea (1990) 1.46
Corneal laser photocoagulation for treatment of neovascularization. Efficacy of 577 nm yellow dye laser. Ophthalmology (1992) 1.44
Ocular rosacea: patient characteristics and follow-up. Ophthalmology (1997) 1.43
Modulation of protein release from chitosan-alginate microcapsules using the pH-sensitive polymer hydroxypropyl methylcellulose acetate succinate. J Microencapsul (1996) 1.41
Long-term follow-up study of mitomycin eye drops as adjunctive treatment of pterygia and its comparison with conjunctival autograft transplantation. Cornea (1990) 1.40
Molecular basis of disease processes. Hum Pathol (2001) 1.39
Fibronectin in healing rabbit corneal wounds. Lab Invest (1981) 1.37
Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev (2001) 1.35
Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology (1980) 1.35
Management of uveitic glaucoma with Ahmed glaucoma valve implantation. Ophthalmology (1999) 1.34
Comparison of mechanical properties of keratoconus and normal corneas. Exp Eye Res (1982) 1.34
Factors influencing predilection and outcome in bacterial keratitis. Cornea (1989) 1.33
Endophthalmitis after keratoprosthesis: incidence, bacterial causes, and risk factors. Arch Ophthalmol (2001) 1.30
The brown bowel syndrome: a possible smooth muscle mitochondrial myopathy? Histopathology (1979) 1.30
Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology (1997) 1.30
Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis (2007) 1.29
Differential expression of voltage-activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro. FEBS Lett (1995) 1.27
Immunopathology of scleritis. Ophthalmology (1991) 1.27
Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol (2000) 1.26
Intermediate uveitis and retinal vasculitis as manifestations of cat scratch disease. Am J Ophthalmol (1996) 1.25
Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management. Cornea (1995) 1.25
Changing patterns in uveitis of childhood. Ophthalmology (1996) 1.24
Concepts of epigenetics in prostate cancer development. Br J Cancer (2008) 1.24
Squamous cell carcinoma of the conjunctiva. Int Ophthalmol Clin (1997) 1.24
Monoclonal antibodies and human tumor pathology. Hum Pathol (1982) 1.24
Miconazole therapy for keratomycosis. Am J Ophthalmol (1981) 1.24
PCR detection of pathogenic viruses in southern California urban rivers. J Appl Microbiol (2004) 1.23
bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol (1996) 1.23
A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo. Prostate Cancer Prostatic Dis (2005) 1.22
Sarcoidosis and its ocular manifestations. Int Ophthalmol Clin (1996) 1.22
Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab (2001) 1.22
Scleritis associated with systemic vasculitic diseases. Ophthalmology (1995) 1.22
Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology (2001) 1.21
Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol (1999) 1.20
Challenges in phenotype definition in the whole-genome era: multivariate models of memory and intelligence. Neuroscience (2009) 1.20
Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. J Immunol (1996) 1.20
Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology (1982) 1.19
Soluble HLA-G circulates in maternal blood during pregnancy. Am J Obstet Gynecol (2000) 1.19
Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells. FEBS Lett (1998) 1.18
Basement membrane components in healing rabbit corneal epithelial wounds: immunofluorescence and ultrastructural studies. J Cell Biol (1984) 1.17
Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol (2000) 1.17
Six cases of scleritis associated with systemic infection. Am J Ophthalmol (1992) 1.16
Amniotic membrane surgery. Curr Opin Ophthalmol (2001) 1.15
Collagen crosslinking in keratoconus. Invest Ophthalmol Vis Sci (1978) 1.15
Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol (1999) 1.15
Penetrating keratoplasty in cicatrizing conjunctival diseases. Ophthalmology (1995) 1.15
Improved detection of disease progression in ocular cicatricial pemphigoid. Cornea (1992) 1.14
Penetrating keratoplasty for herpes simplex keratitis. Am J Ophthalmol (1981) 1.13
Posterior segment ocular manifestations in patients with HLA-B27-associated uveitis. Ophthalmology (1994) 1.13
Immunohistopathologic features and therapy of conjunctival lichen planus. Am J Ophthalmol (1993) 1.13
Visual outcome in eight cases of Serratia marcescens keratitis. Am J Ophthalmol (1981) 1.13
Corneal infection in mucosal scarring disorders and Sjögren's syndrome. Am J Ophthalmol (1988) 1.13
Scleral patch graft in the management of necrotizing scleritis. Int Ophthalmol Clin (1999) 1.13
Genetic studies on murine susceptibility to herpes simplex keratitis. Clin Immunol Immunopathol (1986) 1.13
In vivo and in vitro hepatic 31P magnetic resonance spectroscopy and electron microscopy of the cirrhotic liver. Liver (1997) 1.13
Conjunctival lymphoma masquerading as chronic conjunctivitis. Ophthalmology (1999) 1.12
Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. Am J Ophthalmol (1994) 1.12